A case of lipoprotein glomerulopathy with thrombotic microangiopathy due to malignant hypertension

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Wu, Yu ^a   Chen, Xiaohan ^a   Yang, Yuan ^a   Wang, Baohe ^b   Liu, Xiaoxia ^a   Tao, Ye ^a   Fu, Ping ^a   Hu, Zhangxue ^a  

^a SICHUAN UNIVERSITY   (China)

^b Nuclear Industry 416 Hospital   (China)

Author keywords

APOE Kyoto; Lipoprotein glomerulopathy; Malignant hypertension; Thrombotic microangiopathy

Indexed keywords

GENOMIC DNA; METOPROLOL; NIFEDIPINE; PRAZOSIN; SIMVASTATIN;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CASE REPORT; CHINESE; DNA EXTRACTION; DNA ISOLATION; FEMALE; GLOMERULOPATHY; HUMAN; KIDNEY BIOPSY; LEG EDEMA; LIPOPROTEIN GLOMERULOPATHY; MALIGNANT HYPERTENSION; NEPHROTIC SYNDROME; PALLOR; PROTEINURIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; URINALYSIS;

ADOLESCENT; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; HYPERTENSION; KIDNEY DISEASES; THROMBOTIC MICROANGIOPATHIES; TREATMENT OUTCOME;

EID: 84874353061     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-53     Document Type: Article

References (27)

1. Apolipoprotein E and renal disease. Liberopoulos E, Siamopoulos K, Elisaf M, Am J Kidney Dis 2004 43 2 223 233 10.1053/j.ajkd.2003.10.013 14750087 (Pubitemid 38146320)
2. Etiological significance of apolipoprotein E mutations in lipoprotein glomerulopathy. Saito T, Ishigaki Y, Oikawa S, Yamamoto TT, Trends Cardiovasc Med 2002 12 2 67 70 10.1016/S1050-1738(01)00148-7 11852253 (Pubitemid 34145265)
3. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. Hixson JE, Vernier DT, J Lipid Res 1990 31 3 545 548 2341813 (Pubitemid 20107994)
4. Lipoprotein glomerulopathy: glomerular lipoprotein thrombi in a patient with hyperlipoproteinemia. Saito T, Sato H, Kudo K, Oikawa S, Shibata T, Hara Y, Yoshinaga K, Sakaguchi H, Am J Kidney Dis 1989 13 2 148 153 2644825 (Pubitemid 19063101)
5. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. Saito T, Matsunaga A, Oikawa S, Am J Kidney Dis 2006 47 2 199 211 10.1053/j.ajkd.2005.10.017 16431249 (Pubitemid 43121323)
6. Lipoprotein glomerulopathy: a new apolipoprotein E mutation with enhanced glomerular binding. Sam R, Wu H, Yue L, Mazzone T, Schwartz MM, Arruda JA, Dunea G, Singh AK, Am J Kidney Dis 2006 47 3 539 548 10.1053/j.ajkd.2005.12.031 16490634 (Pubitemid 43255189)
7. Thrombotic microangiopathies, including hemolytic uremic syndrome. Ruggenenti P, Cravedi P, Remuzzi G, Comprehensive clinical nephrology Missouri: Elsevier Saunders, Floege J, Johnson RJ, Feehally J, 4 2010 344 355
8. Pulmonary thrombotic microangiopathy caused by gastric carcinoma. Yokomine T, Hirakawa H, Ozawa E, Shibata K, Nakayama T, J Clin Pathol 2010 63 4 367 369 10.1136/jcp.2010.075739 20354211
9. Renal thrombotic microangiopathy associated with chronic humoral graft versus host disease after hematopoietic stem cell transplantation. Mii A, Shimizu A, Masuda Y, Fujino T, Kaneko T, Utsumi K, Arai T, Ishikawa A, Wakamatsu K, Tajika K, et al. Path Int 2011 61 1 34 41 10.1111/j.1440-1827.2010.02608.x
10. Clinical characteristics and prognosis of diffuse proliferative lupus nephritis with thrombotic microangiopathy. Hu WX, Liu ZZ, Chen HP, Zhang HT, Li LS, Liu ZH, Lupus 2010 19 14 1591 1598 10.1177/0961203310376523 20798137
11. Drug-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a concise review. Dlott JS, Danielson CFM, Blue-Hnidy DE, McCarthy LJ, Ther Apher Dial 2004 8 2 102 111 10.1111/j.1526-0968.2003.00127.x 15255125 (Pubitemid 38796940)
12. Drug-induced thrombocytopenia: a systematic review of published case reports. George JN, Raskob GE, Shah SR, Rizvi M, Hamilton S, Osborne S, Vondracek T, Ann Intern Med 1998 129 11 886 890 9867731 (Pubitemid 28549817)
13. Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Jackson AM, Rose BD, Graff LG, Jacobs JB, Schwartz JH, Strauss GM, Yang JP, Rudnick MR, Elfenbein IB, Narins RG, Ann Intern Med 1984 101 1 41 44 6203452 (Pubitemid 14088065)
14. Clinical features of malignant hypertension with thrombotic microangiopathy. Akimoto T, Muto S, Ito C, Takahashi H, Takeda S, Ando Y, Kusano E, Clin Exp Hypertens 2011 33 2 77 83 10.3109/10641963.2010.503303 21214403
15. Thrombotic microangiopathy and malignant hypertension. Pardo V, Aburano A, Am J Clin Pathol 1966 45 5 605 613 5939953
16. Microangiopathic hemolysis and renal failure in malignant hypertension. van den Born BJ, Honnebier UP, Koopmans RP, van Montfrans GA, Hypertension 2005 45 2 246 251 10.1161/01.HYP.0000151620.17905.ee 15596574 (Pubitemid 40179968)
17. Association between thrombotic microangiopathy and reduced ADAMTS13 activity in malignant hypertension. van den Born BJ, van der Hoeven NV, Groot E, Lenting PJ, Meijers JC, Levi M, van Montfrans GA, Hypertension 2008 51 4 862 866 10.1161/HYPERTENSIONAHA.107.103127 18332284 (Pubitemid 351654696)
18. Thrombotic microangiopathy in malignant hypertension and hemolytic uremic syndrome (HUS)/ thrombotic thrombocytopenic purpura (TTP): can we differentiate one from the other? Shibagaki Y, Fujita T, Hypertens Res 2005 28 1 89 95 10.1291/hypres.28.89 15969259 (Pubitemid 40584967)
19. Complications and survival of 315 patients with malignant-phase hypertension. Lip GY, Beevers M, Beevers DG, J Hypertens 1995 13 8 915 924 10.1097/00004872-199508000-00013 8557970
20. Successful treatment of patients with lipoprotein glomerulopathy by protein A immunoadsorption: a pilot study. Xin Z, Zhihong L, Shijun L, Jinfeng Z, Huiping C, Caihong Z, Daxi J, Leishi L, Nephrol Dial Transplant 2009 24 3 864 869 18840890
21. Lipoprotein glomerulopathy treated with LDL-apheresis (heparin-induced extracorporeal lipoprotein precipitation system): a case report. Russi G, Furci L, Leonelli M, Magistroni R, Romano N, Rivasi P, Albertazzi A, J Med Case Reports 2009 3 9311 10.1186/1752-1947-3-9311
22. Successful treatment of lipoprotein glomerulopathy in a daughter and a mother using niceritrol. Hamatani H, Hiromura K, Kobatake K, Yoshida H, Kobayashi S, Yoneda N, Kayakabe K, Matsumoto T, Kuroiwa T, Ueki K, et al. Clin Exp Nephrol 2010 14 6 619 624 10.1007/s10157-010-0333-9 20842518
23. Improvement of nephrotic syndrome by intensive lipid-lowering therapy in a patient with lipoprotein glomerulopathy. Matsunaga A, Furuyama M, Hashimoto T, Toyoda K, Ogino D, Hayasaka K, Clin Exp Nephrol 2009 13 6 659 662 10.1007/s10157-009-0207-1 19603250
24. Resolution of typical lipoprotein glomerulopathy by intensive lipid-lowering therapy. Ieiri N, Hotta O, Taguma Y, Am J Kidney Dis 2003 41 1 244 249 10.1053/ajkd.2003.50016 12500244 (Pubitemid 36043374)
25. Disappearance of intraglomerular lipoprotein thrombi and marked improvement of nephrotic syndrome by bezafibrate treatment in a patient with lipoprotein glomerulopathy. Arai T, Yamashita S, Yamane M, Manabe N, Matsuzaki T, Kiriyama K, Kanayama Y, Himeno S, Matsuzawa Y, Atherosclerosis 2003 169 2 293 299 10.1016/S0021-9150(03)00194-1 12921981 (Pubitemid 37297476)
26. Thrombotic microangiopathy as a complication of high-dose chemotherapy for breast cancer. Fisher DC, Sherrill GB, Hussein A, Rubin P, Vredenburgh JJ, Elkordy M, Ross M, Petros W, Peters WP, Bone Marrow Transplant 1996 18 1 193 198 8832014 (Pubitemid 26289653)
27. Cancer chemotherapy-related thrombotic thrombocytopenic purpura: biological evidence of increased nitric oxide production. Porta C, Danova M, Riccardi A, Bobbio-Pallavicini E, Ascari E, Mayo Clin Proc 1999 74 6 570 574 10.4065/74.6.570 10377931 (Pubitemid 29264775)